Bristol Flying Solo As A Pure Biopharma After Mead Johnson Spin Out

Decision to split off the nutritionals unit - Bristol's last diversified business - reflects management's improved confidence in the biopharma business and strength of Mead Johnson's stock price.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet